AC
WHWK

Annandale Capital’s Whitehawk Therapeutics WHWK Stock Holding History

Annandale Capital’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,000
Closed -$24K – 157
2023
Q3 		$24K Sell
5,000
-5,000
-50% -$29.1K 0.01% 134
2023
Q2 		$68K Hold
10,000
– – 0.02% 133
2023
Q1 		$72K Hold
10,000
– – 0.02% 128
2022
Q4 		$128K Buy
+10,000
New +$131K 0.04% 119

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Annandale Capital's WHWK Position: Q4 2023 in Review

Annandale Capital sold out of Whitehawk Therapeutics (WHWK) in Q4 2023, closing a stake of 5,000 shares — an estimated $24K sold.

Annandale Capital first reported a position in WHWK in Q4 2022 and held it in 4 quarters. The position peaked at $128K in Q4 2022. 65 funds tracked by Wall St. Rank hold WHWK as of Q4 2023.

  • Annandale Capital reported no remaining Whitehawk Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Annandale Capital sold 5,000 Whitehawk Therapeutics shares in Q4 2023, an estimated $24K.
  • Annandale Capital first reported a position in Whitehawk Therapeutics in Q4 2022 and held it in 4 quarters.
  • Annandale Capital's Whitehawk Therapeutics position peaked at $128K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2023.

Based on Annandale Capital's 13F filing for Q4 2023, filed 14 Feb 2024.